VAPO - Vapotherm, Inc.
9.55 0.00 (0.00%)
After hours: 4:16PM EST
| Previous Close | 9.48 |
| Open | 9.50 |
| Bid | 9.48 x 800 |
| Ask | 9.60 x 1400 |
| Day's Range | 9.26 - 10.20 |
| 52 Week Range | 7.60 - 24.63 |
| Volume | 176,598 |
| Avg. Volume | 211,903 |
| Market Cap | 217.691M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.29 |
| Earnings Date | Jan 23, 2020 - Jan 29, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.67 |
- Simply Wall St.
Is Vapotherm (NYSE:VAPO) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- Business Wire
Vapotherm Reports Third Quarter 2019 Financial Results
Vapotherm, Inc. , a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced its financial and operating results for the third quarter ended September 30, 2019.
- Business Wire
New Study Shows Vapotherm Hi-VNI® Technology Improved In-patient Participant Ambulation Recovery Time by 32.5% Versus Standard Oxygen Therapy
Hi-VNI Technology improved patient distance walked by 12.4% and duration of time walked by 8.5%. Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology, today announced that a paper published in the Journal of Clinical Respiratory Diseases and Care, titled “Assessing the Clinical Effect of High Velocity Nasal Insufflation on Improving Ambulation in Patients with Dyspnea: A Feasibility Study” demonstrated that use of Vapotherm Hi-VNI Technology during ambulation is feasible and showed that patients with dyspnea participating in this study who used Hi-VNI Technology as respiratory support walked farther and recovered faster when compared to standard oxygen treatment.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Vapotherm, Inc. (VAPO)
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
- Business Wire
Vapotherm to Report Third Quarter 2019 Financial Results
Vapotherm, Inc. (VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today that it will release financial results for the third quarter of 2019 after the close of trading on Tuesday, November 5, 2019. Vapotherm’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
- GuruFocus.com
Vapotherm Inc (VAPO) President & CEO Joseph Army Bought $100,000 of Shares
President & CEO of Vapotherm Inc (30-Year Financial, Insider Trades) Joseph Army (insider trades) bought 10,000 shares of VAPO on 09/04/2019 at an average price of $10 a share. Continue reading...
- Zacks
Zacks.com featured highlights include: ACM, K12, Vapotherm, Equity Commonwealth and Columbus McKinnon
Zacks.com featured highlights include: ACM, K12, Vapotherm, Equity Commonwealth and Columbus McKinnon
- Zacks
New Analyst Coverage Puts Spotlight on These 5 Stocks
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
- Simply Wall St.
What Percentage Of Vapotherm, Inc. (NYSE:VAPO) Shares Do Insiders Own?
The big shareholder groups in Vapotherm, Inc. (NYSE:VAPO) have power over the company. Large companies usually have...
Motley FoolVapotherm, Inc. (VAPO) Q2 2019 Earnings Call Transcript
VAPO Vapotherm, Inc. (VAPO) Q2 2019 Earnings Call Transcript
- ACCESSWIRE
Vapotherm, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 29, 2019 / Vapotherm, Inc. (NYSE: VAPO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 29, 2019 at 4:30 PM Eastern ...
- Business Wire
Vapotherm to Present at the William Blair 39th Annual Growth Stock Conference
Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the William Blair 39th Annual Growth Stock Conference on Wednesday, June 5th at the Loews Chicago Hotel in Chicago, Illinois. Vapotherm is scheduled to present at 3:20pm Central Time. A webcast replay of the presentation will be available for 90 days following the presentation in the Event Archive section of Vapotherm’s Investor website at http://investors.vapotherm.com/.
- Motley Fool
Vapotherm Inc (VAPO) Q1 2019 Earnings Call Transcript
VAPO earnings call for the period ending March 31, 2019.
- Business Wire
Vapotherm to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15 at the Encore Hotel in Las Vegas, Nevada. Vapotherm is scheduled to present at 5:15pm Pacific Time. A webcast replay of the presentation will be available for 90 days following the presentation in the Event Archive section of Vapotherm’s Investor website at http://investors.vapotherm.com/.
- Associated Press
Vapotherm: 1Q Earnings Snapshot
On a per-share basis, the Exeter, New Hampshire-based company said it had a loss of 76 cents. The medical technology company posted revenue of $12.3 million in the period. For the current quarter ending ...
- Business Wire
Vapotherm Reports First Quarter 2019 Financial Results
Vapotherm, Inc. , a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced its financial and operating results for the first quarter ended March 31, 2019.
- Simply Wall St.
You Might Like Vapotherm, Inc. (NYSE:VAPO) But Do You Like Its Debt?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investors are always looking for growth in small-cap stocks like Vapotherm, Inc. (NYSE:VAPO), with a...
- Business Wire
Vapotherm to Report First Quarter 2019 Financial Results
Vapotherm, Inc. (VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today that it will release financial results for the first quarter of 2019 after the close of trading on Tuesday, May 7, 2019. Vapotherm’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to a live webcast, please visit the Investors section of the Vapotherm’s website at: http://investors.vapotherm.com/events-and-presentations/events.
- Business Wire
Emergency Department Subgroup Study Showed Hi-VNI® Technology Had Similar Outcomes to Non-invasive Positive Pressure Ventilation in Management of Respiratory Distress Among Acute Decompensated Heart Failure Patients
Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology, today announced that a paper published in the American Journal of Emergency Medicine, titled “HVNI vs NIPPV in the treatment of Acute Decompensated Heart Failure: subgroup analysis of a multi-center trial in the ED” showed equivalent outcomes between Hi-VNI Technology and Non-invasive Positive Pressure Ventilation (NiPPV) in the treatment of respiratory distress in a subgroup of patients suffering from acute decompensated heart failure (ADHF). “These results represent another proof point that Vapotherm Hi-VNI Technology is a viable alternative to relieve undifferentiated respiratory distress across a wide variety of patient populations,” said Joe Army, President and CEO.
- GuruFocus.com
Vapotherm Inc (VAPO) Files 10-K for the Fiscal Year Ended on December 31, 2018
For the last quarter Vapotherm Inc reported a revenue of $42.4 million, compared with the revenue of $30.12 million during the same period a year ago. Warning! GuruFocus has detected 1 Warning Sign with VAPO.
- Associated Press
Vapotherm: 4Q Earnings Snapshot
The Exeter, New Hampshire-based company said it had a loss of $1.39 per share. Losses, adjusted to extinguish debt, came to $1.28 per share. The medical technology company posted revenue of $11.7 million ...
